Hospitals could be turning away high-risk heart patients to help their TAVR programs receive a higher ranking, according to new research published in JACC: Cardiovascular Interventions. 

Semaglutide alters Alzheimer’s biomarkers but doesn’t slow the disease’s advance. 

Some cardiologists feel the specialty is inclusive and nothing needs to change, but not everyone agrees with that sentiment. A new survey detailed the perspective of more than 1,500 cardiologists. 

The recall was put in place after a hydrophilic coating was discovered on the inside of the devices. According to the FDA, patients treated with the catheters could face a number of significant risks. 

The timing of this new guidance from the Heart Rhythm Society and American College of Cardiology could not have been better—the document went live just as CMS finalized its decision to cover cardiac ablation procedures performed in ASCs.

The largest healthcare system in the Middle East is partnering with Nvidia to decode the human genome. If successful, the AI-heavy project will translate almost the entire language of heredity into actionable information.

No other heart or transplant services at the nonprofit hospital should be impacted by this temporary shift in care. 

One of the AI haves feels the pain of the AI have-nots. His discomfort is especially pronounced when he thinks about how hard it must be for financial strugglers to keep up with regulations and rumors of regulations to come.